Your browser doesn't support javascript.
loading
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Fukada, Ippei; Ito, Yoshinori; Kondo, Naoto; Ohtani, Shoichiro; Hattori, Masaya; Tokunaga, Eriko; Matsunami, Nobuki; Mashino, Kohjiro; Kosaka, Taijiro; Tanabe, Masahiko; Yotsumoto, Daisuke; Yamanouchi, Kosho; Sawaki, Masataka; Kashiwaba, Masahiro; Kawabata, Hidetaka; Kuroi, Katsumasa; Morita, Satoshi; Ohno, Shinji; Toi, Masakazu; Masuda, Norikazu.
Afiliação
  • Fukada I; Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. ippei.fukada@jfcr.or.jp.
  • Ito Y; Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Kondo N; Department of Breast Surgery, Nagoya City University Hospital, Nagoya, Aichi, Japan.
  • Ohtani S; Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Hattori M; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan.
  • Tokunaga E; Department of Breast Oncology, National Kyusyu Cancer Center, Fukuoka, Japan.
  • Matsunami N; Department of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan.
  • Mashino K; Department of Breast Surgery, Shuto General Hospital, Yamaguchi, Japan.
  • Kosaka T; Department of Surgery, Oita Prefectural Hospital, Oita, Japan.
  • Tanabe M; Department of Breast Surgery, Juntendo University Nerima Hospital, Tokyo, Japan.
  • Yotsumoto D; Department of Breast Surgery, Hito Medical Center, Ehime, Japan.
  • Yamanouchi K; Department of Breast Oncology, Juntendo University Hospital, Tokyo, Japan.
  • Sawaki M; Department of Breast and Endocrine Surgery, The University of Tokyo Hospital, Tokyo, Japan.
  • Kashiwaba M; Department of Breast Surgery, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan.
  • Kawabata H; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Kuroi K; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan.
  • Morita S; Department of Breast Oncology, Breastopia Miyazaki Hospital, Miyazaki, Japan.
  • Ohno S; Adachi Breast Clinic, Kyoto, Japan.
  • Toi M; Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan.
  • Masuda N; Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Breast Cancer Res Treat ; 190(3): 425-434, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34554370
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antraciclinas Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antraciclinas Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão